News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
517,459 Results
Type
Article (44204)
Company Profile (130)
Press Release (473125)
Section
Business (144709)
Career Advice (2380)
Deals (27882)
Drug Delivery (107)
Drug Development (67749)
Employer Resources (148)
FDA (15541)
Job Trends (11925)
News (263158)
Policy (29551)
Tag
Academia (2282)
Alliances (35718)
Alzheimer's disease (1281)
Approvals (15446)
Artificial intelligence (121)
Bankruptcy (300)
Best Places to Work (9106)
Biotechnology (82)
Breast cancer (112)
Cancer (1024)
Cardiovascular disease (96)
Career advice (1988)
Cell therapy (231)
Clinical research (53679)
Collaboration (335)
Compensation (197)
COVID-19 (2544)
C-suite (90)
Data (1026)
Diabetes (151)
Diagnostics (5085)
Drug pricing (97)
Earnings (57144)
Employer resources (136)
Events (74626)
Executive appointments (265)
FDA (16061)
Funding (281)
Gene therapy (183)
GLP-1 (643)
Government (3793)
Healthcare (14691)
Infectious disease (2629)
Inflammatory bowel disease (101)
Interviews (444)
IPO (13791)
Job creations (3152)
Job search strategy (1660)
Layoffs (450)
Legal (6902)
Lung cancer (166)
Manufacturing (169)
Medical device (11053)
Medtech (11056)
Mergers & acquisitions (14152)
Metabolic disorders (436)
Neuroscience (1552)
NextGen Class of 2024 (4969)
Non-profit (3156)
Northern California (1343)
Obesity (257)
Opinion (188)
Patents (100)
People (41801)
Phase I (16001)
Phase II (23237)
Phase III (19132)
Pipeline (451)
Policy (86)
Postmarket research (2193)
Preclinical (6483)
Radiopharmaceuticals (201)
Rare diseases (220)
Real estate (4247)
Regulatory (20192)
Research institute (2048)
Resumes & cover letters (400)
Southern California (1147)
Startups (2735)
United States (11655)
Vaccines (618)
Weight loss (212)
Date
Today (117)
Last 7 days (761)
Last 30 days (3491)
Last 365 days (31587)
2024 (28986)
2023 (34983)
2022 (45060)
2021 (48501)
2020 (45514)
2019 (36216)
2018 (27398)
2017 (27813)
2016 (25804)
2015 (27975)
2014 (21777)
2013 (17793)
2012 (18968)
2011 (19381)
2010 (17506)
Location
Africa (667)
Arizona (137)
Asia (30487)
Australia (5337)
California (2922)
Canada (953)
China (184)
Colorado (125)
Connecticut (148)
Europe (74006)
Florida (415)
Georgia (99)
Illinois (260)
Indiana (152)
Maryland (532)
Massachusetts (2299)
Michigan (118)
Minnesota (215)
New Jersey (845)
New York (821)
North Carolina (638)
Northern California (1343)
Ohio (109)
Pennsylvania (734)
South America (1032)
Southern California (1147)
Texas (393)
Washington State (320)
517,459 Results for "almirall prodesfarma s a".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Almirall’s Nine-Month 2024 Results: Almirall Reports Strong Performance at Q3 2024 - Driven by Successful Commercial Execution of the Dermatology Portfolio, Fuelled by Biologics Growth
November 11, 2024
·
7 min read
FDA
FDA Approves Almirall’s Klisyri® (tirbanibulin) for the Treatment of Actinic Keratosis on Expanded Area of Face or Scalp up to 100 cm2
Almirall, a global pharmaceutical company dedicated to medical dermatology, announced that the U.S. Food and Drug Administration has approved Almirall’s recent supplemental New Drug Application to expand the use area for its drug, Klisyri, to up to 100 cm2.
June 10, 2024
·
6 min read
Business
Almirall’s Nine-month 2023 Results:
Almirall, S.A., the global biopharmaceutical company based in Barcelona, has announced its 9M 2023.
November 9, 2023
·
19 min read
Press Releases
New Data Show Almirall´s EBGLYSS® (Lebrikizumab) Provided Sustained Disease Control for up to Three Years in More Than 80% of Adults and Adolescents With Moderate-to-severe Atopic Dermatitis
September 25, 2024
·
8 min read
Press Releases
Almirall Announces Completion of Decentralized Regulatory Approval Procedure for Efinaconazole in Europe
October 15, 2024
·
4 min read
Business
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases
Almirall, S.A. and Eloxx Pharmaceuticals, Inc. announced that the companies have entered into an exclusive license agreement for the asset ZKN-013.
March 13, 2024
·
7 min read
Almirall Delivers Strong Start of 2024 – Q1 Net Sales Growth of 6.6% Overall and 18% in the European Dermatology Business, Driven by Biologics and Solid Performance of Broad Product Portfolio
Almirall, S.A. a global biopharmaceutical company based in Barcelona, announced its financial results from the first quarter 2024.
May 13, 2024
·
6 min read
Press Releases
Almirall to Present New Data on Biologics for Psoriasis and Atopic Dermatitis and Celebrates 80 Years of Innovation at the EADV Congress
September 23, 2024
·
11 min read
Business
Almirall’s First Quarter 2023 Results
Almirall, S.A., the global biopharmaceutical company based in Barcelona, has announced its Q1 2023 financial results.
May 8, 2023
·
11 min read
Business
Novo Licenses to Almirall Potential First-in-Class Antibody Candidate
Almirall will have exclusive global rights to develop and commercialize the anti-IL-21 monoclonal antibody NN-8828 in several fields, including immune inflammatory dermatological indications.
February 19, 2024
·
2 min read
·
Tristan Manalac
1 of 51,746
Next
